Table 2.

Baseline prevalence of pyrazinamide resistance among subjects in a TB cohort study in Lima, by baseline resistance pattern.

Resistance pattern	Total No.	PZA resistance No.	% PZA resistance % (95% CI)
Pan-susceptible to all FLD	2191	0	0 (0–0.2)*
Monoresistant	466	3	0.6 (0.1–1.9)
Polyresistant to FLD, not MDR-TB	213	21	9.9 (6.2–14.7)
Resistant to two FLD	187	9	4.8 (2.2–8.9)
Resistant to three or more FLD	26	12	46.2 (26.6–66.6)
MDR-TB	405	193	47.7 (42.7–52.6)
Incomplete DST to FLD†	2	0	0 (0–84.2)*
Total	3277	217	6.6 (5.8–7.5)

DST=drug susceptibility testing; FLD=first-line drugs (isoniazid, rifampin, ethambutol, pyrazinamide, and streptomycin); MDR-TB=multidrug-resistant tuberculosis; PZA=pyrazinamide.

^*One-sided, 97.5% confidence interval.

^†One patient had missing DST to rifampin and streptomycin, and another patient had missing DST to streptomycin.